Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer.

91 , 92 At the prespecified primary data analysis, treatment with ivonescimab/chemotherapy resulted in significant improvement in PFS (HR 0.52, 95% CI 0.41-0.66, P < 0.00001), with a favorable trend for OS (HR 0.79, 95% CI 0.62-1.01) that did not achieve statistical significance. 90 The primary analysis of OS was event driven and conducted at a time when the median follow-up for the overall population was 29.7 months, but was 9.2 months for the subgroup of patients from North America and Europ

also in 993 other papers